<DOC>
	<DOC>NCT02396316</DOC>
	<brief_summary>To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.</brief_summary>
	<brief_title>Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Neovascular</mesh_term>
	<criteria>Japanese men and women aged 20 years or older, Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle), Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization. Patients with angleclosure due to conditions other than Neovascular glaucoma Patients with a known or suspected ocular or periocular infection, Patients with severe intraocular inflammation in the study eye, Women who are pregnant, suspected of being pregnant or lactating, Patients with known allergy to aflibercept.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>